Skip to content

Monkey studies confirm viability of injectable PrEP drug

Chasity Andrews, from the Aaron Diamond Research Institute in New York, and Gerardo-Garcia-Lerma, from the Centers for Disease Control in Atlanta, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Sofosbuvir & ribavirin cures 75% of genotype 1 HIV/HCV co-infected patients

Susanna Naggie from Duke Clinical Research Institute presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

AbbVie '3D' combination cures 99% of genotype 1b hepatitis C

Prof. Rajendar Reddy, of the University of Pennsylvania Hospital, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Simeprevir cures almost 80% of first-time co-infected hepatitis C patients

Prof. Douglas Dieterich of Mount Sinai School of Medicine discusses recent advances in treatment of hepatitis C and HIV co-infection at CROI 2014. Photo by Liz Highleyman / hivandhepatitis.com

Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection

Douglas Dieterich, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Six-week oral treatment can cure hard-to-treat hepatitis C patients

Anita Kohli, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

No-one with an undetectable viral load, gay or heterosexual, transmits HIV in first two years of PARTNER study

Press conference at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

A cure may need multiple components, workshop delegates hear

A cure may need multiple components, workshop delegates hear

TB-HIV news from the 44th Union World Conference on Lung Health.